Genprex, Inc.
GNPXNasdaq
$7.67
↓ -4.1%Jul 17 close · end-of-day
Price
1Y↓ -97.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$53.3M
Enterprise Value
$35.3M
P/E
—
P/S
—
P/B
3.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$16.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-98.8%
ROIC
—
Debt / Equity
—
Net Cash
$18.0M
Return 1Y
-97.5%
Company profile
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
- CEO
- J. Rodney Varner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Texas
- Website
- genprex.com
Management & directors
- Berger Mark StanleyChief Medical Officer
- Confer Ryan M.President, CEO and CFO
Roles derived from SEC Form 4 filings.
Earnings
GNPX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.0M | -$20.7M | -$23.8M | -$31.1M | -$21.2M | -$15.5M |
| Net income | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$13.9M | -$14.3M | -$17.6M | -$24.7M | -$17.9M | -$15.3M |
| Free cash flow | -$14.0M | -$14.3M | -$17.6M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.5M | -$4.3M | -$4.3M | -$4.0M | -$4.7M | -$3.3M | -$3.5M | -$4.5M |
| Net income | -$6.5M | -$4.3M | -$4.3M | -$4.0M | -$4.7M | -$3.8M | -$3.8M | -$4.5M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$6.6M | -$2.2M | -$3.9M | -$4.2M | -$3.9M | -$3.2M | -$4.1M | -$3.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-14 | LONGNECKER BRENT M | Sale | 10 | $1.23 | $12.30 | filing |
| 2026-04-14 | LONGNECKER BRENT M | Sale | 8 | $1.23 | $9.84 | filing |
| 2026-02-27 | Confer Ryan M.· President, CEO and CFO | Tax withholding | 9,330 | $2.00 | $18,660.00 | filing |
| 2026-02-27 | Berger Mark Stanley· Chief Medical Officer | Tax withholding | 7,168 | $2.00 | $14,336.00 | filing |
| 2025-12-22 | Wilson William R Jr. | Award | 9,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | Berger Mark Stanley· Chief Medical Officer | Award | 28,500 | $0.00 | $0.00 | filing |
| 2025-12-22 | Moreno Toscano Jose Antonio | Award | 9,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | Confer Ryan M.· President, CEO and CFO | Award | 45,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | LONGNECKER BRENT M | Award | 9,000 | $0.00 | $0.00 | filing |
| 2025-06-30 | Confer Ryan M.· President, CEO and CFO | Tax withholding | 5,775 | $0.23 | $1,316.12 | filing |
| 2025-06-30 | Berger Mark Stanley· Chief Medical Officer | Tax withholding | 4,500 | $0.23 | $1,025.55 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.